• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Venus Concept Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/14/25 4:11:27 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    false0001409269NASDAQ00014092692025-08-142025-08-14

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 14, 2025


    VENUS CONCEPT INC.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-38238
    06-1681204
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification Number)

    235 Yorkland Blvd , Suite 900
    Toronto, Ontario M2J 4Y8
    (Address of principal executive offices, including Zip Code)

    Registrant’s telephone number, including area code: (877) 848-8430

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share
     
    VERO
     
    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02.
    Results of Operations and Financial Condition.

    On August 14, 2025, Venus Concept Inc. issued a press release relating to its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01.
    Financial Statements and Exhibits.

    Exhibit
    No.
    Description
       
    99.1
    Pres release dated August 14, 2025
       
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
       


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    VENUS CONCEPT INC.
         
    Date: August 14, 2025
    By:
     /s/ Michael Mandarello
       
    Michael Mandarello
       
    Chief Legal Officer & Head of Strategy & Operations



    Get the next $VERO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP ("Madryn") for 545,335 shares of its Series Y preferred stock. Following the transaction, the Company had total debt obligations of approximately $30.1 million, a reduction of 24% compared to $39.7 million outstanding as of December 31, 2024. "Madryn's invaluable partnership has provided us with financial flexibility as we work towards sustained long

    10/2/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of Financial Results & Recent Progress: Total revenue for the second quarter of $15.7 million, down 5% year-over-year and up 15% quarter-over-quarter U.S. revenue up $0.4 million, or 5%, year-over-year driven by growth in cash systems sales of $1.0 million, or 23%, year-over-year Second quarter GAAP net loss of $11.7 million, compared to $19.9 million last yearSecond quarter Adjusted EBITDA loss of $8.8 million, compared to $4.1

    8/14/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    7/2/25 7:27:23 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    4/2/25 5:47:31 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    SEC Filings

    View All

    Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Venus Concept Inc. (0001409269) (Filer)

    10/2/25 4:11:17 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - Venus Concept Inc. (0001409269) (Filer)

    9/22/25 5:01:03 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Venus Concept Inc. (0001409269) (Filer)

    9/3/25 4:16:22 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care